We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Cell and Gene Therapy Catapult, UCLB and Imperial Innovations Announce Positive Interim Review

News   Apr 13, 2016

 
Cell and Gene Therapy Catapult, UCLB and Imperial Innovations Announce Positive Interim Review
 
 
Advertisement
 

RELATED ARTICLES

Increase in Genome-Editing Trials Means Change for Informed Consent Process

News

Researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, asked patients, parents and physicians in the sickle cell disease community what they wanted and needed to know about genome editing to make informed decisions about participating in genome-editing clinical trials.

READ MORE

Neoantigens Could Be Key to Unlocking a New Generation of Immunotherapies

News

Scientists have discovered parameters to better predict which neoantigens can stimulate a cancer-killing effect.

READ MORE

Value and Applicability of Spectroscopy in Biopharmaceuticals and Product Development

News

A new collaborative study from RedshiftBio (Burlington, MA) and a Major Pharmaceutical Company published in the Journal of Pharmaceutical Sciences provides compelling evidence of the benefits of the award winning AQS3™pro, a Microfluidic Modulation Spectroscopy platform from RedShift BioAnalytics, Inc., for the biopharmaceutical industry.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE